

## CURRICULUM VITAE

### Mary Redman, Ph.D.

Current Address: Southwest Oncology Group Statistical Center  
Fred Hutchinson Cancer Research Center  
1100 Fairview Avenue N., M3-C102  
Seattle, WA 98109-1024

Phone: Office: (206) 667-4623

E-mail: mredman@fhcrc.org

Education: University of Washington, B.S. (Mathematics), 1997  
University of Washington, M.S. (Biostatistics), 2000  
University of Washington, Ph.D. (Biostatistics), 2004

#### POSITIONS

Assistant Member, Fred Hutchinson Cancer Research Center, 2005 – present

Postdoctoral Fellow, University of Washington, 2004 – 2005

Staff Scientist, International AIDS Research and Training Program, University of Washington, 2004 – 2005  
*Statistician for investigators into correlates of mother-to-child transmission of HIV-1 in Kenya.*

Statistical Consultant, United States Department of Veteran Affairs, 2000 – 2002  
*Analysis and manuscript collaboration for an observational study of treatment of diabetic foot ulcers; planning for a clinical trial of ulcer treatment regimes amount diabetics.*

Research/Teaching Assistant, International AIDS Research and Training Program, University of Washington, 2002-2004  
*Mentoring and tutoring for international physicians pursuing the MPH degree; statistical analysis and manuscript collaboration for various international AIDS and STI studies and grant proposals.*

Statistical Consultant, School of Dentistry, University of Washington, 2002  
*Analysis of the association between periodontitis and preterm, low birth-weight babies.*

Statistical Consultant, Qiagen Genomics, Bothell, Washington, 1999 – 2000  
*Developed a model-based clustering algorithm for high throughput SNP genotyping.*

Research Assistant, HPV Research Group, University of Washington, 1997 – 2002  
*Statistician and data manager for a study of HIV-1 infected MSM, investigating the relationship between HAART and anal dysplasia; statistician for projects in Senegal comparing aspects of HIV-1 and HIV-2 infection: SAS programmer.*

## STATISTICAL INTERESTS

Causal inferences from observational data; time-varying treatment effects; time-dependent confounding; instrumental variables and generalized method of moments estimation.

## PROFESSIONAL SOCIETIES

American Statistical Association  
International Biometrics Society

## BIBLIOGRAPHY

Publications in refereed journals:

1. Gottlieb GS, Sow PS, Hawes SE, Ndoye I, Redman, M, et al. Equal plasma viral loads predict a similar rate of CD4+ T Cell decline in human immunodeficiency virus (HIV) type 1- and HIV-2-infected individuals from Senegal, West Africa. *J Infect Dis* 185(7):905-914, 2002.
2. Brumback BA, Greenland SG, Redman MW, Kiviat N, Diehr, P. The intensity-score approach to adjusting for confounding. *Biometrics* 59(2):274-285, 2003.
3. Casper C, Redman MW, Huang M, et al. HIV infection and human herpesvirus 8 (HHV-8) oral shedding among men who have sex with men. *J Acquir Immune Defic Syndr* 35(3):233-238, 2004.
4. Farquhar C, Rowland-Jones S, Mbori-Ngacha D, Redman, M, et al. Human leukocyte antigen (HLA) B\*18 and protection against mother-to-child HIV-1 transmission. *AIDS Res Hum Retroviruses* 20(7):692-697, 2004.
5. Farquhar C, Mbori-Ngacha D, Redman M, et al. CC and CXC chemokines in breast milk are associated with mother-to-child HIV-1 transmission. *Current HIV Research* Oct;3(4):361-9, 2005.
6. Moinpour CM, Donaldson GW, Redman MW. Do general dimensions of quality of life add clinical value to symptom data? *J Natl Cancer Inst Monogr* 37:31-38, 2007. PMID: 17951229
7. Redman M, Crowley J. Small randomized trials. *J Thorac Oncol* 2(1):1-2, 2007. PMID: 17410001
8. Thompson IM, Jr, Lucia MS, Redman MW, Darke A, La Rosa FG, Parnes HL, Lippman SM, Coltman CA. Finasteride decreases the risk of prostatic intraepithelial neoplasia. *J Urol* 178:107-110, 2007. PMID: 17499284
9. Moinpour CM, Hayden KA, Unger JM, Thompson IM, Jr, Redman MW, Canby-Higano ED, Higgins BA, Sullivan JW, Lemmon D, Breslin S, Crawford ED. Health-related quality of life results in pathologic stage C prostate cancer from a Southwest Oncology Group trial comparing radical prostatectomy alone with radical prostatectomy plus radiation therapy. *J Clin Oncol* 26(1):112-120, 2008. PMID: 18165645
10. Lara PN, Jr, Redman MW, Kelly K, Edelman MJ, Williamson SK, Crowley JJ, Gandara DR. Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials. *J Clin Oncol* 26(3):463-467, 2008. PMID: 18202421
11. Redman MW, Tangen CM, Goodman PJ, Lucia MS, Coltman CA, Jr, Thompson IM. Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach. *Cancer Prev Res* 1(3):174-181, 2008. PMID: 19138953. PMCID: PMC2844801.
12. Mack P, Redman M, Chansky K, Williamson S, Farneth N, Lara PN, Jr, Franklin WA, Le Q-T, Crowley JJ, Gandara D. Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG study S0003. *J Clin Oncol* 26(29):4771-4776, 2008. PMID: 18779603. PMCID: PMC2653139.

13. Misono S, Weiss NS, Fann JR, Redman M, Yueh B. Incidence of suicide in persons with cancer. *J Clin Oncol* 26(29):4731-4738, 2008. PMID: 18695257. PMCID: PMC2653137.
14. Shepherd BF, Redman MW, Ankerst DP. Does finasteride affect the severity of prostate cancer? a causal sensitivity analysis. *J Amer Stat Assoc* 103(484):1392-1404, 2008. No PMID designated
15. Le Q-TX, Moon J, Redman M, Williamson SK, Lara PN, Jr, Goldberg Z, Gaspar LE, Crowley JJ, Moore DF, Jr, Gandara DR. Phase II study of tirapazamine, cisplatin, and etoposide and concurrent thoracic radiotherapy for limited-stage small-cell lung cancer: SWOG 0222. *J Clin Oncol* 27(18):3014-3019, 2009. PMID: 19364954. PMCID: PMC2702233.
16. Lara PN, Jr, Natale R, Crowley J, Lenz H-J, Redman MW, Carleton JE, Jett J, Langer CJ, Kuebler JP, Dakhil SR, Chansky K, Gandara DR. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. *J Clin Oncol* 27(15):2530-2535, 2009. PMID: 19349543; PMCID: PMC2684855
17. Moinpour CM, Vaught NL, Goldman B, Redman MW, Philip PA, Millwood B, Lippman SM, Seay TE, Flynn PJ, O'Reilly EM, Rowland KM, Wong RP, Benedetti J, Blanke CD. Pain and emotional well-being outcomes in Southwest Oncology Group-directed intergroup trial S0205: a phase III study of gemcitabine plus cetuximab versus gemcitabine as first-line therapy in patients with advanced pancreas cancer. *J Clin Oncol* 28(22):3611-3616, 2010. PMID: 20606094, PMCID: PMC2917316
18. Herbst RS, Kelly K, Chansky K, Mack PC, Franklin WA, Hirsch FR, Atkins JN, Dakhil SR, Albain KS, Kim ES, Redman M, Crowley JJ, Gandara DR. Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342. *J Clin Oncol* 28(31):4747-4754, 2010. PMID: 20921467
19. Lara PN, Jr, Chansky K, Shibata T, Fukuda H, Tamura T, Crowley J, Redman MW, Natale R, Saijo N, Gandara DR. Common arm comparative outcomes analysis of Phase 3 trials of cisplatin + irinotecan versus cisplatin + etoposide in extensive stage small cell lung cancer; final patient-level results from Japan Clinical Oncology Group 9511 and Southwest Oncology Group 0124. *Cancer* 116(24):5710-5715, 2010. PMID: 20737417, PMCID: PMC2994945

In Press:

1. Redman MW and Crowley JJ. Clinical Trials Design. In: Shilds TW, LoCicero III J, Reed CE, Geins RH, eds. *General Thoracic Surgery*, 7th ed.

Submitted:

1. Redman MW, Richardson BA, John-Stewart GC, Hudgens M, et al. Controlling the false positive rate in determining CD8+ T to HIV. Submitted to *Journal of Immunological Methods*

In preparation:

1. Wu K, Redman MW. Sensitivity of treatment effect estimates on the specification of propensity score model and assumed underlying causal model.
2. Redman MW and LeBlanc M. Measures of variable importance: On the use of G-estimation to assess continuous biomarkers measured pre- and post-treatment.
3. Redman MW, Thompson IM. Accounting for multiple biases and High grade prostate cancer in the PCPT. To be submitted to *NEJM*.
4. Redman MW, Crowley J, Lara P, Gandara D. Is innovative design the way forward for targeted therapies?

5. McGregor BA, Syrjala KL, Langer SL, Dolan ED, Redman MW. The effect of pre-transplant distress on immune reconstitution among adult hematopoietic cell transplantation patients.

## PRESENTATIONS AND POSTERS

### Invited:

1. Brumback BA, Greenland S, Redman M, Kiviat N, Diehr, P. The intensity-score approach to adjusting for confounding. Workshop on Causal Inference, University of Ghent, Belgium, June 2001.
2. Brumback BA, Greenland S, Redman M, Kiviat N, Diehr P. The intensity-score approach to adjusting for confounding. Causal Inference Conference, Snowbird, UT, August 2001.
3. Redman, MW, Heymach J. Phase II into Phase III trials. International association for the study of lung cancer, Workshop. Seoul, Korea, September 2007.
4. Redman MW. Analysis of pharmacogenomic data in cancer clinical trials. JMTO. Japan September 2007.
5. Redman MW. Causal subgroup modeling in cancer clinical trials. ENAR annual meeting. Washington, D.C. March 2008.

### Selected contributed:

1. Redman M, Brumback BA, Greenland S, Kiviat N, Diehr P. The intensity-score approach to adjusting for confounding. International Conference on Health Policy Research, Boston, MA 2001.
2. Brumback BA, Greenland S, Redman M, Kiviat N, Diehr P. A causal model for effect-measure modification by treatment indication Society for Epidemiologic Research Meeting, Palm Desert, CA, 2005.
3. Redman MW, Brumback BA. Inference when the probability of treatment is estimated. Joint Statistical Meetings, San Francisco, CA, 2003.
4. Shepherd B, Redman MW, and Ankerst DP. The Causal Effect of Finasteride on the Severity of Prostate Cancer. Joint Statistical Meetings, Seattle, WA 2006.
5. Lara PN, Redman MW, Kelly K, Edelman MJ, Williamson SK, Crowley JJ, and Gandara DR. Alternative measures predicting clinical benefit in advanced non-small cell lung cancer (NSCLC) from Southwest Oncology Group (SWOG) randomized trials: Implications for clinical trial design. *Journal of Clinical Oncology*, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S, 2006: 7006
6. Mack PC, Redman MW, Chansky K, Williamson SK, Farneth N, Lara PN, Le Q, Gumerlock PH, Crowley JJ, Gandara DR. Elevated osteopontin (OPN) plasma levels are highly prognostic in advanced non-small cell lung cancer (NSCLC): Analysis of SWOG S0003. *Journal of Clinical Oncology*, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 7198

### Posters:

1. Casper C, Redman M, Huang M, Pauk J, Corey L, Kiviat N, Wald A. Predictors of human herpesvirus Eight (HHV-8) oral shedding among human immunodeficiency virus (HIV) seropositive men. Presented at: Infection Diseases Society of America, 39th Annual Meeting, 2001.
2. Hawes S, Critchlow C, Redman M, Sow P, Kiviat N. A longitudinal study of the detection of human immunodeficiency virus (HIV) type 1 and type 2 RNA in vaginal secretions among Senegalese women. Presented at: 9th Conference on Retroviruses and Opportunistic Infections, February 2002.

3. Hawes S, Redman M, Lampinen T, Nelson P, Critchlow C, Kiviat N. The effect of highly active antiretroviral therapy (HAART) on detection of anal papillomavirus (HPV) and squamous intraepithelial lesions (SIL) among HIV-infected homosexual men. Presented at: Society of Epidemiologic Research, Palm Desert, CA June 2002.

#### TEACHING ACTIVITIES

University of Washington, Biost 511 guest lecturer. Spring 2006, 2007.

University of Washington, Epi 586 guest lecturer, Fall 2005-2007.

Supervise Research Assistant, Dept. of Biostatistics, University of Washington, June 2006 – present.

### Summary of other activities:

In the last year, I gave two lectures for classes at the University of Washington; one in Biostat 111 Lectures in Applied Statistics and the other in Epi 590 Responsible Conduct of International Research. A 3<sup>rd</sup> year graduate student in the department of Biostatistics, Kenneth Wu starting working with me in the summer as a research assistant. He is currently learning the fundamentals of causal inference for point-source treatments and performing sensitivity analyses to compare various estimators. We will then be extending my dissertation methods to more complex settings. I have also been working with Bryan Shepherd, an assistant professor at Vanderbilt and Donna P. Ankerst to extend and apply Bryan's methods to the Prostate Cancer Prevention trial data. This should result in an interesting analysis and discussion of the effect of finasteride on severity of prostate cancer. I also took the lead on one of the aims in Mike LeBlanc's R01 re-submitted in November. This aim focuses primarily on methods for the analysis longitudinal biomarker processes and patient outcome data in long term studies. Finally, I have continued my collaborations with Bonnie McGregor. The data that she will generate in her studies should provide some interesting methodic challenges applicable to my work.